NCT00850577 2015-10-12
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 2 Terminated
Clinical Trials
3 trialsNCT00851045 2015-10-12
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT00562419 2010-10-27
CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
Adnexus, A Bristol-Myers Squibb R&D Company
Phase 2 Unknown